PGEN vs VIR
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
PGEN · Precigen$4.21 ▲ 1.20%
VIR · Vir Biotechnology$8.39 ▼ 5.41%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- PGEN +10.2%
- VIR +37.1%
Head to head
| Metric | PGEN | VIR |
|---|---|---|
| Price | $4.21 | $8.39 |
| Change today | ▲ 1.20% | ▼ 5.41% |
| Market cap | $1.51B | $1.56B |
| Return, 3 months | -41.3% | -15.3% |
| Return, year to date | +0.7% | +39.1% |
| Return, 1 year | +8.5% | +47.7% |
| P/E (TTM) | 38.3 | – |
| P/B | 18.0 | 1.7 |
| P/E percentile vs own 5y | 100th | 11th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +2,437.6% | -207.7% |
| Net profit growth (YoY) | +124.4% | +41.0% |
| Gross margin | 91.4% | 100.0% |
| Operating margin | 21.4% | -69.9% |
| Net margin | 15.6% | -61.1% |
| Return on equity | 38.8% | -21.8% |
| Analyst target vs. price | +232.5% | +167.3% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 32 | 33 |
| 30-day volatility | 117.7% | 92.6% |
| Max drawdown, 1 year | -51.4% | -38.5% |
| Trend read | Strong downtrend | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- VIR is the largest of the group by market value.
- VIR has returned the most over the past year.
- PGEN is growing revenue fastest.
- PGEN keeps the most profit per dollar of sales.
- VIR has been the calmest stock over the last 30 days.